Katerina Samara

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher, Tamera J. Corte, Aryeh Fischer et al. · The Lancet Respiratory Medicine · 2019 · 606 citations

Antifibrotic Therapy, Advanced Lung Disease, Pulmonary Fibrosis +3

NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung

Ismini Lasithiotaki, Ioannis Giannarakis, Eliza Tsitoura et al. · European Respiratory Journal · 2016 · 128 citations · Full text

Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis

Katerina Samara · International Journal of Oncology · 2012 · 81 citations · Full text

Inflammatory Lung Disease, Lung Inflammation, Tlr3 Mrna Expression +22

Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean “real-life” experience

Eleni Tzortzaki, Andreas Georgiou, Dimitrios Kampas et al. · Pulmonary Pharmacology & Therapeutics · 2011 · 71 citations

Asthma, Allergy, Allergy Medicine +6

Oxidative DNA Damage and Somatic Mutations

Eleni Tzortzaki, Katerina Dimakou, Eirini Neofytou et al. · CHEST Journal · 2011 · 63 citations

Genome Instability, Dna Damage, Somatic Mutations +10